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1. Abstract 
1.1. English abstract 
This diploma thesis is part of the Postgraduate Department "Biomedical 
Research Methodology, Biostatistics and Clinical Bioinformatics" and aims to 
highlight the relationship of procalcitonin and mortality in ICU patients with sepsis. 
 Its subject is the design of a prospective observational study protocol. Patients 
participating in the study will be in intensive care center units having already 
experienced a septic stage. The hospitals that will be used are: General Hospital of Volos, 
General Hospital of Larissa and General University Hospital of Larissa   
 Along with the writing of the thesis, an Access database will be created where 
the PCT measurements will be recorded according to the study timetable, thus making 
the statistical analysis and the management - publication of the results easier. In this 
way, it is possible to draw conclusions about the relationship of procalcitonin and 
mortality. 
Key words: sepsis, procalcitonin, mortality, ICU 
1.2. Greek abstract 
Η παξνύζα εξγαζία απνηειεί θνκκάηη ηνπ Μεηαπηπρηαθνύ Τκήκαηνο 
«Μεζνδνινγία Βηνταηξηθήο Έξεπλαο,  Βηνζηαηηζηηθή θαη Κιηληθή Βηνπιεξνθνξηθή» 
θαη έρεη σο ζηόρν ηελ αλάδεημε ηεο  ζρέζεο πξνθαιζηηνλίλεο θαη ζλεζηκόηεηαο ζε 
αζζελείο ηεο ΜΕΘ κε ζήςε.       
 Αληηθείκελν είλαη ν ζρεδηαζκόο ελόο πξσηνθόιινπ κειέηεο παξαηήξεζεο γηα 
κία πξννπηηθή κειέηε. Οη αζζελείο πνπ ζα ζπκκεηάζρνπλ ζηελ κειέηε ζα βξίζθνληαη 
ζε κνλάδεο εληαηηθήο ζεξαπείαο θέληξσλ πγείαο θαη ζα παξνπζηάδνπλ ήδε έλα ζηάδην 
ζήςεο. Τα λνζνθνκεία πνπ ζα εμεηαζηνύλ είλαη ηα: Γεληθό Ννζνθνκείν Βόινπ, 
Γεληθό Ννζνθνκείν Λάξηζαο θαη ηέινο ην Παλεπηζηεκηαθό Ννζνθνκείν Λάξηζαο. 
 Παξάιιεια κε ηελ ζπγγξαθή ηεο εξγαζίαο, δεκηνπξγήζεθε θαη κία βάζε 
δεδνκέλσλ Access όπνπ ζα γίλεηαη ε θαηαρώξεζε ησλ κεηξήζεσλ ηεο PCT ζύκθσλα 
κε ην ρξνλνδηάγξακκα ηεο κειέηεο κε απνηέιεζκα λα είλαη πην έπθνιε ε ζηαηηζηηθή 
αλάιπζε θαη ε δηαρείξηζε – έθδνζε ησλ απνηειεζκάησλ. Με απηό ηνλ ηξόπν ζα 
κπνξέζεη λα γίλεη θαη ε εμαγσγή ζπκπεξαζκάησλ γηα ηελ ζρέζε ηεο πξνθαιζηηνληλεο 
θαη ηνπ ζαλάηνπ. 
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Λέξειρ κλειδιά: ζήψη, πποκαλζιηονίνη, θνηζιμόηηηα, ΜΕΘ 
2. Introduction 
In this chapter, basic information will be presented on the theoretical 
background of the postgraduate dissertation. More specifically, the definitions of 
sepsis, PCT will be analyzed. 
2.1. Sepsis 
Sepsis is a dramatic change of an infection which can lead to death. It has four 
steps: SIRS, Sepsis, Severe sepsis, septic shock and mortality rate in sepsis remains 
extremely high. Early diagnosis is critical in order to reduce mortality associated with 
sepsis. Diagnostic uncertainty sometimes still remains high despite the available 
clinical information which leads to laboratory measurements where serum biomarkers 
like procalcitonin may aid in the early diagnosis of sepsis and therapeutic 
intervention.          
 If sepsis progresses to septic shock, which is the last step, then blood pressure 
drops dramatically and may lead to death. Sepsis is more common and most 
dangerous in elder people or those who already suffer a weakened immune system. In 
the end, if sepsis is treated early, most common with antibiotics and intravenous fluids 
then the risk of mortality is drastically decreased. 
 
Picture 1 Stages of sepsis 
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2.1.1. Sepsis risk factors 
The most common risk factors of sepsis are based on:  
 the age of the patient (either very young or very old),    
 the state of the patient’s immune system, 
 the state of the patient’s sickness level ( Intensive care unit),   
 patient’s injuries (burns, severe cuts etc),     
 patient’s invasive devices(catheters or breathing tubes) 
2.2. Procalcitonin 
Procalcitonin (PCT) is a protein that consists of 116 amino acids and forms the 
protein precursor form of calcitonin. It is produced and secreted by the thyroid gland 
and physiologically is undetectable in the blood of healthy individuals. In response to 
infection and systemic inflammation, the secretion of Procalcitonin in the bloodstream 
increases and in combination with proteolytic enzymes break down into the active 
hormone, calcitonin. After infection, procalcitonin is increased in a short time. 
  
 
Picture 2 : Production pathway of PCT and CT in healthy and infected individuals 
 When inflammation is caused by a bacterial infection, the presence of 
procalcitonin is particularly important because it is also released from the liver, 
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kidneys, lungs, muscles and fatty tissue, elevating serum levels of procalcitonin 
significantly above normal. Thus, measuring procalcitonin is useful in the 
differentiation of bacterial infections from other pathological conditions and has 
proven to be more sensitive and specific marker for this purpose, relative to C-
reactive protein (CRP). 
 The level of procalcitonin rises in a response to a proinflammatory state. It is 
often classed as an acute phase reactant. Blood levels of procalcitonin may rise  up to 
100 µg/L. As a matter of fact, monitoring of serum procalcitonin levels may be 
particularly useful in monitoring the response to antibiotic therapy. 
2.2.1. Limitations of procalcitonin 
 There is a number of limitations where using procalcitonin as a marker of 
infection and sepsis. High measurements in PCT levels where there is absence of a 
bacterial infection can take place in situations like stress, after surgery, or in patients 
with cardiac shock.       
 That is the reason why the power of procalcitonin to discriminate between 
sepsis and sterile inflammation is better for medical than for surgical patients. 
2.3. Procalcitonin and sepsis 
Procalcitonin has been used in Europe and US (FDA) for many years as a 
diagnostic aid for sepsis and has recently become of interest as a possible marker of 
the systemic inflammatory response to infection. Procalcitonin gained an FDA 
indication in 2016 for serial use to assess sepsis progression and 28-day mortality risk.  
2.4. Possible Interpretation of Pathological values procalcitionin 
levels 
 <0.50 ng / mL do not rule out the infection, as localized inflammations can be 
combined with such values.   
> 2.0 ng / mL are indicative of systemic bacterial infection or severe localized 
inflammation. Levels> 2.0 ng / mL may be related also with trauma, burn, multi-
organ failure. 
> 10.0 ng / mL are indicative of septicemia. 
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Guidelines for initiating antibiotics according to PCT value 




Antibiotics discouraged Antibiotics encouraged Antibiotics strongly 
encouraged 
Guidelines for stopping, continuing or changing antibiotics according to daily measured PCT 
value 
< 0.25 ng/ml  Decline more than 80% or 
80% of peak (maximum) 
value or ≥ 0.25 to < 0.5 ng/ml 
Decline of PCT less than 
80% of peak value and 
PCT ≥ 0.5 ng/ml 
Increase of PCT 
above previous and 
PCT ≥ 0.5 ng/ml 
Table 1 PCT and antibiotics guidelines [
17
] 
2.5. Prospective or retrospective?  
A prospective cohort study is a study that follows over time a group of similar 
individuals (cohorts) who differ with respect to certain factors under study, to 
determine how these factors affect rates of a certain outcome. 
  A retrospective cohort study, is a study where a  cohort of individuals that 
share a common exposure factor is compared to another group of equivalent 
individuals not exposed, in order to determine the factor's influence on the incidence 
of a condition such as disease or death.      
 The reason that the study is prospective is that those type of studies provide 
future proof for biomarkers (which is the key point of our study) and has also strong 
validity where a retrospective study could provide fast data but there could be 
potential bias (missing data etc.) 
 
2.6. Cohort study 
In these studies, all people in the surveyed population are ranked in one 
exposure category at the start of the follow-up period. The exposure classification 
may be bitsome, ie exposed / un-exposed or may include many categories (un-
exposed, little exposed, very exposed). These individuals are monitored for a 
specified period and all new cases of the disease under study are identified. 
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3. Methods 
This chapter will demonstrate all the information about the patients and the 
study and will be divided into seven subchapters. As mentioned in the Abstract 
(Chapter 1) an MS Access Database will be created to accompany the patient’s CRF’s 
and lead the way for further statistical analysis. 
3.1. Interventions  
Procalcitonin was measured daily over the first 5 days. Primary blood 
measurement should occur in the first 12 hours (Baseline PCT) after the severe sepsis 
or septic shock is detected. This point is critical as antibiotics shouldn’t be delayed. 
3.2. Study design 
The study design is prospective for six months, multicenter observational 
clinical trial. Three hospitals will take place in the study: 
I. General Hospital of Volos 
II. General Hospital of Larissa 
III. General University Hospital of Larissa 
Each hospital will have a defined sample size of patients which will be 
computed in the next subchapter (3.4 Sample Size). 
 
 
Picture 3 Study design 
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3.3. Study discontinuation 
Basic reasons for the termination of the study are:  
 Ethical concerns (will also be mentioned in the sub-chapter 3.4.1),  
 alterations in accepted clinical practice,  
 reaching a positive or negative statistical end point earlier than expected  
 lack of funding.  
Last but not least, the discontinuation of a clinical trial can be decided by either 
the investigator, the study sponsor, or by mutual agreement. 
3.4. Sample size 
Based on Demirdal et al 2018, the mean PCT value for septic ICU patients that 
survived was [5.7±13.7 ng/dL] and [10.1 ± 18.0] for the non survivors. Thus, we need 
an 100 % increase in the study group mean value, leading us to a sample of n=61 
patients. 
𝑁 =







𝑁 = 61 
Having three different hospitals where the sample can be gathered, it will be 
divided proportionally based on demographic criteria. More specifically, two hospitals 
are based in Larissa (Greece) and one in Volos (Greece). The proportions will be set 
to 66,7% and 33,3%, n1=21, n2= 20 and n3= 20.     
 The power of the study is set to 90% and p-value at 0.05 
3.5. Patients 
Patients meeting criteria for severe sepsis or septic shock who were admitted 
to the ICU from the emergency department, other hospital clinics, or directly from out 
of hospital were included. Minimum three hospitals will be included in the study. 
Consecutive sampling will be used for all patients until we reach the sample size 
which was calculated in the previous subchapter.   
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3.5.1. Inclusion criteria 
Inclusion criteria for this study were adult patients who were diagnosed with 
severe sepsis or septic shock. Those patients were either treated in the ICU or were 
transferred there from the emergency department or even out of the hospital. 
 Blood sampling performed within the first 12 hours after diagnosis of severe 
sepsis or septic shock and at last, their or their escort’s willingness to provide written 
informed consent.  
3.5.2. Exclusion criteria 
Patients without initial blood draw, unwilling to provide written informed 
consent were excluded.  
3.5.3. Subject’s withdrawal 
Every subject has the right to withdraw from the study anytime. By the time 
this occurs, all of the following research activities involving the subject’s participation 
such as:  
 Interaction with the subject in order to obtain data   
 additional identifiable private information  
will be stopped. In addition, patients might be withdrawn by the investigator if the 
investigator feels that the patient is not gaining any clinical benefit or because of 
unacceptable toxicity. Patients who are withdrawn or are removed from the study will 
be required to have an off-study clinic visit at the time of discontinuation, a 30-day 
follow-up safety visit. 
3.6. Flow chart 
Each patient that enters the Intensive Care Unit in each of the three medical 
centers is controlled whether meets the inclusion criteria or not. If they meet all the 
criteria, then they can enter the study. If they do not, then we proceed to the 
consecutive sampling until all the three sub samples are gathered. Below there is a 
flow chart that demonstrates the “route” of its patient. 
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Picture 4 Flow chart 
3.7. Access Database 
As mentioned in the introduction, a database will also escort the monitoring of 
the study and the recording data on each CRF. The primal reason for this is to assure 
that the single data entry with second look is registered properly so that a clear 
outcome could be drawn in a very short time.     
 Due to the fact that the sample size is not very large, not many specialized 
staff is required thus the implementation of this database could provide us instant data 
for queries that the operator could set such as:  
 mean PCT value,  
 mortality (survivors – nonsurvivors),    
 average days in the ICU 
 age 
 gender  
 antibiotics used etc. 
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Below is an example of a query where instant patient outcome is provided. 
The database searches all the patients that are included in the study and their outcome 
which is also fulfilled from the personnel.       
 This query can be adjusted by date and even measure monthly, annually etc. 
outcomes. Such queries can be generated by the data exported from the CRF’s. 
 
SELECT Patient.Fullname, Patient.Outcome, Patient.[ExportDate] 
FROM Patient 
WHERE (((Patient.[ExportDate]) Between #  /  /2018# And # /  /2018#)); 
 
 
Picture 5 Form in MS Access for daily PCT measurement 
In picture 5, a simple form of daily PCT measurement is demonstrated. By 
keeping records of those forms, the operator can extract results for the PCT value such 
as: 
 minimum PCT value 
 maximum PCT value 
 Average PCT value etc. 
that can be combined with factors such as age, gender or even Medical History for 
further statistical analysis ( Chapter 4 –Results). 
4. Results 
4.1. Statistical analysis 
 
The entire patient’s data will be recorded for this study: 
 Age 
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 Gender 
 Sepsis stage 
 PCT measurement (5 days) 
 Antibiotics 
 Days in ICU 
 Outcome 
For the quantitative variables, descriptive statistics will produce mean value, 
median, quartiles, standard deviation, 95% CI and extreme values. As for the 
categorical values, proportions will be measured.       












Antibiotics Days in 
ICU 
Outcome 
- - - - - - - - - - - - 
Table 2 Patients primary measurements 
4.2. Evaluation 
At the end of the study, survival analysis will be performed as the event of 
study is mortality. Patients will be followed over the period of the study. Focus will 
be on the time that the event occurs, where the closest PCT value that will be 
recorded, will indicate us a relationship between PCT and mortality. Linear regression 
cannot be used as it cannot effectively handle the censored observations. 
 
Picture 6 Incident Rate 
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A plot about PCT concentration will be created for survivors and non-suvivors 
demonstrating the 95% confidence interval:   
 LL (Lower Limit) 
 UL (Upper Limit) 
 Mean (Mean value) 
 
Picture 7 Daily PCT concentration 
4.3. Study limitations  
As the study is observational, non-randomized, different biases may occur that 
can potentially introduce channeling bias and confuse the relationship between 
procalcitonin and the risk of the safety outcome (mortality). 
5. Discussion 
This diploma dissertation presented a draft protocol with the aim to examine 
the relationship between procalcitonin and mortality in septic ICU patients. Basic 
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information about sepsis, procalcitonin was presented in the “Introduction” chapter as 
well as the definitions of prospective and retrospective type of studies with their pros 
and cons.          
 Also, in “Methods” chapter a flow chart was designed based on the inclusion-
exclusion criteria of the study. Study’s sample size was calculated based on a recent 
study about procalcitonin and bacteremia prediction in Intensive care units. Last but 
not least, a Microsoft Access Database was created in order to escort the data fulfilled 
in the Case Report/Record Forms and strengthen the integrity of the results. With such 
combination, further research could use the database’s data for other studies subjects.
 To sum up, it is known that procalcitonin is a prognostic marker for sepsis, 
what we need to study is not only its relationship with mortality but also a 
multivariate analysis with gender – age – and mortality. 
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